American biotechnology firm Moderna Inc. has inked an agreement to build a state-of-the-art messenger RNA vaccine manufacturing facility in Canada, the company announced in a statement.

  • The agreement was inked with the Canadian government, in an effort to provide the country access to domestically made vaccines that fight respiratory viruses. It will also give Canada access to Moderna’s mRNA development engine.
  • The facility will also be activated on an “urgent basis” to support Canada’s efforts against COVID-19. Vaccines to be made in the facility also cater to seasonal influenza, respiratory syncytial virus, and potential other vaccines.
  • Moderna Chief Executive Stephane Bancel said the partnership will bring about global impact and implications, as the company remains committed to working with governments amid the COVID-19 pandemic.

Moderna’s COVID-19 vaccine recorded 93% efficacy, which remained stable six months after the second dose. MRNA is down 1.67%.